Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy

HIV Clinical Trials

Volumn 11, Issue 6, 2010, Pages 340-350

  Raboud, Janet ^a,b   Blitz, Sandra ^a   Walmsley, Sharon ^a,b,c   Thompson, Courtney ^c   Rourke, Sean B ^b,d,e   Loutfy, Mona R ^b,c,f,g  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ONTARIO HIV TREATMENT NETWORK   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f MAPLE LEAF MEDICAL CLINIC   (Canada)

^g WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

antiretroviral na ve; calendar year; gender; HIV; virologic rebound; virologic suppression

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREGNANCY TERMINATION; PRIORITY JOURNAL; SEX RATIO; TREATMENT OUTCOME; VIRUS TRANSMISSION;

ADULT; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ONTARIO; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEASONS; SEX FACTORS; TIME FACTORS; VIRAL LOAD;

EID: 78751554189     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1106-340     Document Type: Article

References (38)

1. Public Health Agency of Canada. HIV and AIDS in Canada. Surveillance Report to December 31, 2008. Surveillance and Risk Assessment Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada; 2009.
2. CDC Epidemiology of HIV/AIDS - United States, 1981 - 2005. MMWR. 2006;55(21):589-592.
3. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2007. Vol 19. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2009.
4. European Centre for the Epidemiological Monitoring of AIDS. HIV/AIDS Surveillance in Europe. End-Year Report 2000. France: Institut de Veille Sanitaire; 2001: No. 64.
5. European Centre for Disease Prevention and Control/ WHO Regional Offi ce for Europe. HIV/AIDS Surveillance in Europe 2008. Stockholm: European Centre for Disease Prevention and Control; 2009.
6. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization 2009. AIDS Epidemic Update 2009. Geneva: UNAIDS.
7. dArminio Monforte A, Gonzalez L, Haberl A, Sherr L, Ssanyu-Sseruma W, Walmsley SL. Better mind the gap: addressing the shortage of HIV positive women in clinical trials. AIDS. 2010;24(8):1091-1094.
8. Collazos J, Asensi V, Cartón JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS. 2007;21(7):835-843.
9. Nicastri E, Leone S, Angeletti C, et al. Sex issues in HIV-1 infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrobial Chemother. 2007;60:724-732.
10. Currier J, Bridge DA, Hagins D, et al, on behalf of the GRACE Study Group. Sex-based outcomes of darunavirritonavir therapy. Ann Intern Med. 2010;13:349-357.
11. Struble K, Soon G, Min M, Chan-Tack K, Murray J, Bimkrant D. Meta-analysis of effi cacy outcomes for treatmentnaïve and treatment-experienced HIV-infected women in randomized controlled clinical trials: 2000 to 2008. Conf Retroviruses Opportunistic Infect. 2009;15:987b.
12. Rachlis AR, Zarowny DP. Guidelines for antiretroviral therapy for HIV infection: Canadian HIV Trials Network Antiretroviral Working Group. CMAJ. 1998;158(4):496-505.
13. Donnelly CA, Bartley LM, Ghani AC,. Gender difference in HIV-1 RNA viral loads. HIV Med. 2005;6:170-178.
14. Napravnik S, Poole C, Thomas JC, Eron JJ Jr. Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defi c Syndr. 2002;31:11-19.
15. Rezza G, Lepri AC, d'Arminio Monforte A, et al. Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection. J Acquir Immune Defi c Syndr. 2000;25:56-62.
16. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001;344(10):720-725.
17. Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, Greenblatt RM. Does patient sex affect human immunodefi ciency virus levels? Clin Infect Dis. 2002;35:313-322.
18. 4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med. 1996;335(15):1091-1098.
19. 4 cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med. 2004;140:256-264.
20. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defi c Syndr. 2000;24(5):475-482.
21. Moore AL, Kirk O, Johnson AM, et al; EuroSIDA group. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defi c Syndr. 2003;32:452-461.
22. Nicastri E, Angeletti C, Palmisano L, et al; and the Italian Antiretroviral Treatment Group. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS. 2005;19:577-583.
23. Moore AL, Mocroft A, Madge S, et al. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. J Acquir Immune Defi c Syndr. 2001; 26:159-163.
24. Moore AL, Sabin CA, Johnson MA, Phillips AN. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defi c Syndr. 2002;29(2):197-202.
25. Burger D, Felderhof M, Phanupak P, Duncombe C, et al. Both short-term virological effi cacy and drug-associated nephrotoxicity are related to indinavir (IDV) pharmacokinetics (PK) in HIV-1-infected Thai patients [abstract 730]. Conf Retroviruses Opportunistic Infect. 2001;8:264.
26. Ribera E, Lopez RM, Diaz M, Pou L, et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavirin human immunodefi ciency virus-infected adults. Antimicrob Agents Chemother. 2004;48(11): 4256-4262.
27. Anastos K, Schneider MF, Gange SJ, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005;39(5):537-544.
28. Geretti AM, Smith C, Haberi A, et al. Determinants of virological failure after successful viral load suppression in fi rst-line highly active antiretroviral therapy. Antiviral Ther. 2008;13: 927-936.
29. Kuyper LM, Wood E, Montaner JS, Yip B, O'Connell JM, Hogg RS. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIVInfected patients in a population-based cohort. J Acquir Immune Defi c Syndr. 2004;37(4):1470-1476.
30. Boyd MA. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS. 2009;4:194-199.
31. Lampe FC, Gatell JM, Staszewski S, et al. Changes over time in risk of initial virological failure of combination antiretroviral treatment. A multi-cohort analysis, 1996 to 2002. Arch Intern Med. 2006;166(5):521-528.
32. Bannister WP, Kirk O, Gatell JM, et al; and the Eurosida Group. Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr. 2006;42:229-237.
33. Vo TTN, Ledergerber B, Keiser O, et al; and the Swiss HIV Cohort Study. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis. 2008;197:1685-1694.
34. Furler MD, Einarson TR, Millson M, Walmsley S, Bendayan R. Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDS. 2004;18(4): 215-228.
35. Malta M, Magnanini MMF, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14:731-747.
36. Wood E, Montaner JSG, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected drug users. CMAJ. 2003;169(7):656-661.
37. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251-259.
38. Raboud JM, Su D, Walmsley S, et al. Representativeness of the Ontario Cohort Study of the clinics from which they are recruiting. Presented at: Ontario HIV Treatment Network Research Conference; November 15, 2010; Toronto, Ontario.